PL3598975T3 - Nowe kombinacje antagonisty H3 i inhibitora wychwytu zwrotnego noradrenaliny oraz ich zastosowania terapeutyczne - Google Patents

Nowe kombinacje antagonisty H3 i inhibitora wychwytu zwrotnego noradrenaliny oraz ich zastosowania terapeutyczne

Info

Publication number
PL3598975T3
PL3598975T3 PL18306017T PL18306017T PL3598975T3 PL 3598975 T3 PL3598975 T3 PL 3598975T3 PL 18306017 T PL18306017 T PL 18306017T PL 18306017 T PL18306017 T PL 18306017T PL 3598975 T3 PL3598975 T3 PL 3598975T3
Authority
PL
Poland
Prior art keywords
antagonist
reuptake inhibitor
novel combinations
noradrenaline reuptake
therapeutical uses
Prior art date
Application number
PL18306017T
Other languages
English (en)
Inventor
Xavier Ligneau
Laurent LANDAIS
David Perrin
Jeanne Marie Lecomte
Jean Charles Schwartz
Original Assignee
Bioprojet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet filed Critical Bioprojet
Publication of PL3598975T3 publication Critical patent/PL3598975T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4453Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18306017T 2018-07-27 2018-07-27 Nowe kombinacje antagonisty H3 i inhibitora wychwytu zwrotnego noradrenaliny oraz ich zastosowania terapeutyczne PL3598975T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18306017.7A EP3598975B1 (en) 2018-07-27 2018-07-27 Novel combinations of a h3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof

Publications (1)

Publication Number Publication Date
PL3598975T3 true PL3598975T3 (pl) 2021-04-19

Family

ID=63144936

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18306017T PL3598975T3 (pl) 2018-07-27 2018-07-27 Nowe kombinacje antagonisty H3 i inhibitora wychwytu zwrotnego noradrenaliny oraz ich zastosowania terapeutyczne

Country Status (19)

Country Link
US (2) US11229632B2 (pl)
EP (1) EP3598975B1 (pl)
JP (1) JP7509520B2 (pl)
KR (1) KR102841963B1 (pl)
CN (1) CN110772515A (pl)
AU (1) AU2019208166B2 (pl)
BR (1) BR102019015415A2 (pl)
CA (1) CA3050590A1 (pl)
DK (1) DK3598975T3 (pl)
ES (1) ES2840253T3 (pl)
HU (1) HUE052652T2 (pl)
IL (1) IL268208B (pl)
MA (1) MA46500B1 (pl)
MX (1) MX379400B (pl)
PL (1) PL3598975T3 (pl)
PT (1) PT3598975T (pl)
TN (1) TN2019000216A1 (pl)
TW (2) TWI887204B (pl)
ZA (1) ZA201904876B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3378858A1 (en) * 2017-03-21 2018-09-26 Bioprojet Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same
JP7234955B2 (ja) 2020-01-31 2023-03-08 トヨタ自動車株式会社 車両
WO2022159629A1 (en) * 2021-01-20 2022-07-28 Alto Neuroscience, Inc. Combination drug strategy for the treatment of psychiatric and neurological disorders in which anhedonia or motivation- related dysfunction exists
US20240398777A1 (en) * 2023-06-01 2024-12-05 Harmony Biosciences, Llc Method of treating symptoms of prader-willi syndrome
WO2025082974A1 (en) * 2023-10-16 2025-04-24 Bioprojet Pharma New formulations of pitolisant and methods of use
WO2025162430A1 (zh) * 2024-02-01 2025-08-07 重庆罗特司光电科技有限公司 一种药物联用及其在预防或治疗神经退行性疾病中的用途
WO2025207664A1 (en) * 2024-03-25 2025-10-02 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
EP1717233A1 (en) 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1717234A1 (en) 2005-04-29 2006-11-02 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP3239138A1 (en) * 2016-04-25 2017-11-01 Sandoz Ag Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
EP3378477A1 (en) 2017-03-21 2018-09-26 BIOPROJET Pharma New therapeutical use of h3-ligands
EP3378858A1 (en) 2017-03-21 2018-09-26 Bioprojet Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same

Also Published As

Publication number Publication date
AU2019208166B2 (en) 2024-08-01
IL268208B (en) 2022-09-01
TWI905542B (zh) 2025-11-21
MA46500A1 (fr) 2021-01-29
KR20200012781A (ko) 2020-02-05
JP7509520B2 (ja) 2024-07-02
BR102019015415A2 (pt) 2020-01-28
HUE052652T2 (hu) 2021-05-28
EP3598975B1 (en) 2020-10-21
CN110772515A (zh) 2020-02-11
DK3598975T3 (da) 2020-11-02
US20220079932A1 (en) 2022-03-17
TN2019000216A1 (en) 2021-01-07
RU2019123563A (ru) 2021-01-26
US11229632B2 (en) 2022-01-25
JP2020015724A (ja) 2020-01-30
ES2840253T3 (es) 2021-07-06
EP3598975A1 (en) 2020-01-29
ZA201904876B (en) 2020-05-27
PT3598975T (pt) 2020-12-21
KR102841963B1 (ko) 2025-08-04
TWI887204B (zh) 2025-06-21
IL268208A (en) 2019-11-28
TW202007395A (zh) 2020-02-16
AU2019208166A1 (en) 2020-02-13
MX2019008637A (es) 2020-01-28
MX379400B (es) 2025-03-11
US20200030310A1 (en) 2020-01-30
US12059416B2 (en) 2024-08-13
CA3050590A1 (en) 2020-01-27
TW202404587A (zh) 2024-02-01
MA46500B1 (fr) 2022-07-29

Similar Documents

Publication Publication Date Title
IL268208A (en) Novel combinations of H3 antagonist and noradrenaline reuptake inhibitor and their medical uses
IL283608A (en) 15-pgdh inhibitor
ZA202004769B (en) Bisulfite-free, base-resolution identification of cytosine modifications
EP3574828B8 (en) Monitoring the performance of physical exercises
IL285177A (en) compounds and their use
IL286497A (en) compounds and their use
GB201803568D0 (en) Novel compounds and uses
GB201800473D0 (en) Knowledge base construction
IL291499A (en) Azaquinoline compounds and their uses
SG11202006252YA (en) Hyper-branched compounds, synthesis and uses thereof
SG11202108079RA (en) Compounds and uses thereof
IL284764A (en) compounds and their uses
IT201900023937A1 (it) Procedimento per la preparazione di Lasmiditan e di un intermedio di sintesi
SG11202101308QA (en) Novel magnesium-serinate compound and use thereof
IL283105A (en) Combination of MCL-1 inhibitor and midostearoin, its uses and pharmaceutical preparations
GB201801102D0 (en) New compounds and uses
PL4069923T3 (pl) Oprawa zamka
IT201700059261A1 (it) Piatto compostabile e procedimento per la produzione di un piatto compostabile.
ZA202201239B (en) Aminothiolester compounds and uses thereof
IL281882A (en) Microdosing
PL3917337T3 (pl) Tabletka bulionowa
GB201806349D0 (en) New compounds and uses
GB201916963D0 (en) Well abandonment
GB201900758D0 (en) Well abandonment
UA42037S (uk) Ключ розвідний